Spark Therapeutics is focused on developing gene therapy to accelerate healthcare transformation. It combines a proprietary adeno-associated viral (AAV) gene therapy platform with research and development, manufacturing, and commercial operations.

Spark Therapeutics

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Spark Therapeutics	Alnylam Pharmaceuticals, Inc.
Symbol		ALNY
MSH ID	COM:SPARKTX	COM:ALNYLAM
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Post-IPO
Employee Count		2.10K
Website	sparktx.com	alnylam.com
LinkedIn
Founders

Metric
Market Cap		32.60B
Enterprise Value
Monthly Web Traffic	15.75K	55.97K
Web Traffic Growth	0.98	0.89
Valuation
Raised Capital	380.40M	900M

Metric
Revenue		1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.52B
EBITDA		-228.12M
Operating Income		-282.18M
Net Income		-440.24M
EPS		-3.52
Diluted EPS		-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.87
Operating Profit Margin		0.04
EBITDA Margin		-0.12
Net Profit Margin		-0.03
Return on Equity		1.67
Return on Assets		-0.02
Return on Capital Employed		0.03

COM:SPARKTX

Spark Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-42.10
P/B Ratio		-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		16.84
EV Multiple		326.32

Metric
Days Sales Outstanding		68.92
Days Payables Outstanding		97.72
Days Inventory Outstanding		128.53
Operating Cycle		187.09
Cash Conversion Cycle		104.98
Asset Turnover		0.58

Metric
Operating Cash Flow		104.16M
Free Cash Flow		41.95M
Cash Flow to Debt		0.15
Operating Cash Flow/Sales		0.16
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		812.69M
Accounts Receivable		-87.94M
Inventory		89.15M
Goodwill
Debt to Capitalization		1.20
Debt to Assets		0.34
Current Ratio		3.14
Quick Ratio		3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.13
R&D to Revenue		0.58
SG&A to Revenue		0.35